- Home
- SANG vs CGEN Comparison
SANG vs CGEN Comparison
Compare SANG & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANG
- CGEN
- Stock Information
- Founded
- SANG 1984
- CGEN 1993
- Country
- SANG Canada
- CGEN Israel
- Employees
- SANG N/A
- CGEN N/A
- Industry
- SANG Computer Software: Programming Data Processing
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SANG Technology
- CGEN Health Care
- Exchange
- SANG Nasdaq
- CGEN Nasdaq
- Market Cap
- SANG 189.6M
- CGEN 167.4M
- IPO Year
- SANG 2021
- CGEN 2000
- Fundamental
- Price
- SANG $6.00
- CGEN $1.73
- Analyst Decision
- SANG
- CGEN
- Analyst Count
- SANG 0
- CGEN 0
- Target Price
- SANG N/A
- CGEN N/A
- AVG Volume (30 Days)
- SANG 2.7K
- CGEN 265.3K
- Earning Date
- SANG 05-08-2025
- CGEN 08-05-2025
- Dividend Yield
- SANG N/A
- CGEN N/A
- EPS Growth
- SANG N/A
- CGEN N/A
- EPS
- SANG N/A
- CGEN N/A
- Revenue
- SANG $238,264,000.00
- CGEN $27,589,000.00
- Revenue This Year
- SANG N/A
- CGEN N/A
- Revenue Next Year
- SANG $2.91
- CGEN $173.80
- P/E Ratio
- SANG N/A
- CGEN N/A
- Revenue Growth
- SANG N/A
- CGEN N/A
- 52 Week Low
- SANG $4.08
- CGEN $1.13
- 52 Week High
- SANG $7.99
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- SANG 60.10
- CGEN 57.84
- Support Level
- SANG $5.61
- CGEN $1.62
- Resistance Level
- SANG $6.37
- CGEN $1.81
- Average True Range (ATR)
- SANG 0.11
- CGEN 0.08
- MACD
- SANG 0.02
- CGEN -0.00
- Stochastic Oscillator
- SANG 54.88
- CGEN 65.22
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.